Articles tagged with Breast Cancer
Researchers use molecular imaging to improve diagnosis and treatment decisions for estrogen-receptor positive breast cancer patients, detecting bone metastases and predicting therapy response. PET imaging with 18F-FES and 18F-FDG improves diagnostic information and prompts changes in treatment for 88% and 48% of subjects respectively.
Research by Sheila Collins and colleagues found that cardiac natriuretic peptides cause white fat cells to take on characteristics of brown fat cells, increasing energy usage. In another study, Anne Müller's team identified a cellular mechanism by which Helicobacter pylori protects against asthma by modulating immune cells.
A study found exemestane significantly worsens age-related decreases in bone mineral density by three times, even with adequate calcium and vitamin D intake.
Researchers have uncovered new genetic evidence supporting the hypothesis that acral melanoma is a distinct subtype with UV-damage signatures. Whole-exome sequencing of pancreatic cancer cell lines revealed a significant correlation between loss of MLH1 gene and indel mutation rates, disrupting several well-known cancer genes.
A new study reveals substantial differences in follow-up surgeries for women with breast cancer, affecting cancer recurrence and overall survival rates. The research highlights the need for quality measures to compare breast cancer surgical outcomes among surgeons and hospitals.
A new study reveals substantial differences in follow-up surgeries for women with breast cancer after partial mastectomy, which cannot be explained by medical or treatment history. The variation affects both cancer recurrence and overall survival rates, highlighting the need for increased accountability and transparency in healthcare.
A study of 64,659 women found that only 173 received recommended breast screening MRI despite being at high enough risk. The researchers aim to understand the disconnect and assess the value, feasibility, and implementation of breast MRI screening.
Researchers found significant variation in reexcision rates among surgeons and institutions, with some hospitals performing up to 70% more reexcisions than others. The study highlights the need for increased accountability and transparency in healthcare outcomes.
Researchers report that a short course of vaccination with an anti-HER2 dendritic cell vaccine eradicates tumors in nearly 20% of women with ductal carcinoma in situ. The treatment triggers strong, lasting immune responses in over 85% of patients, potentially reducing the risk of invasive cancer.
Researchers found that Avastin and Sutent, anti-angiogenesis drugs, increase cancer stem cells in breast tumors, fueling growth and spread. The study suggests combining these drugs with cancer stem cell inhibitors may enhance treatment effectiveness.
Researchers discovered 13 new gene regions associated with menopause onset, providing insights into reproductive lifespan and conditions like breast cancer and heart disease. Early menopause is linked to increased risk of these diseases, while later menopause may provide protection.
A study published in the Journal of the National Cancer Institute found that younger breast cancer patients experience more severe mental health issues and physical impairments than older women. Researchers recommend educating these patients about potential post-treatment effects to reduce anxiety and improve quality of life.
A commonly used medication for enlarged prostates may also slow the progression of early-stage prostate cancer, according to a new study. The treatment, dutasteride, was found to delay disease progression and reduce anxiety related to the disease in patients undergoing active surveillance.
A study published in the Journal of the National Cancer Institute found that younger women with breast cancer experience decreased health-related quality of life, including increased psychological distress, weight gain, and early onset menopause. Personalized treatment approaches are crucial to mitigate these side effects.
Statins, cholesterol-lowering medications, have been shown to inhibit the growth of breast cancer cells with mutant p53 genes. By targeting a specific pathway involved in cell proliferation, statins may be effective in treating these types of tumors.
A new imaging platform has been developed by Lawson researchers to study the moment when cancer cells turn deadly. The approach uses a shell-less chick embryo model implanted with human cancer cells, allowing scientists to modulate and monitor protein effects in real-time.
A world-first study conducted by QUT and CSIRO found that temperature-related deaths in Brisbane account for 6,572 years of life lost annually. Improving housing conditions through better insulation can help mitigate this issue.
Researchers identified a biochemical chain of events leading to activation of a protein-cleaving enzyme called hepsin on the surface of breast tumor cells. Hepsin breaks down basement membrane proteins, allowing tumor cells to escape and invade surrounding tissues.
A new study finds that pericytes, a group of cells in the tumor microenvironment, play a crucial role in preventing cancer progression and metastasis. Researchers discovered that inhibiting these cells can inadvertently make tumors more aggressive and likely to spread.
Researchers found that combining lapatinib and trastuzumab improved pathologic complete response rates in early-stage HER2-positive breast cancer patients compared to single-agent treatment. The study suggests dual HER2 blockade as a more effective approach for patients with early, non-metastatic HER2 breast cancer.
A study has identified a protein called hepsin that may trigger the spread of breast cancer in certain cases. Hepsin, a protease enzyme, was found to free tumor cells from their native tissue matrix, allowing them to invade other tissues and grow into aggressive tumors.
New studies published in The Lancet Oncology and The Lancet show that combining lapatinib with trastuzumab is almost twice as effective as single-agent therapy, but causes more side effects. Lapatinib is less beneficial than trastuzumab for single-agent therapy.
A possible receptor for the key breast cancer regulator Tumor Differentiating Factor (TDF) has been identified by researchers at Clarkson University. The receptor, labeled TDF-R, is found exclusively in breast cancer cells and shows specificity, suggesting its potential as a target for new therapies.
Researchers have developed targeted, fluorescent molecular imaging probes that can non-invasively detect breast cancer lymph node metastases, improving breast cancer staging and prognosis. CAIX and CAXII cell surface markers are highly expressed in breast cancer lymph node metastases.
Research finds that ISG15 pathway disrupts cytoskeletal architecture in breast cancer cells, promoting cell migration and invasion. The study suggests that targeting the ISG15 pathway could provide a therapeutic advantage for patients with metastatic tumors.
Research found parabens in breast tissue of all study participants, regardless of underarm product use, indicating alternative sources. The study detected five common paraben esters in 60% of samples and high levels of n-propylparaben near the armpit.
A study found that early-stage breast cancer patients often lacked knowledge about their disease and were not meaningfully involved in treatment discussions. This can lead to treatments not aligning with patient preferences, highlighting the need for improvements in the surgical decision-making process.
A new study found that most parents who get tested for breast cancer genes share their results with their children, even if they are very young. The majority of parents shared their results with at least one child, with older children more likely to be informed than younger ones.
A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The signature was able to distinguish between low and high malignancy risk groups, correlating with good or poor overall survival rates.
A prospective surveillance model for breast cancer treatment has been shown to significantly reduce costs and improve outcomes. The model, which involves early identification and intervention of lymphedema-related impairment, has been associated with direct treatment costs of $636.19 per year compared to traditional care at $3,124.92.
A Concordia-led research team found that Lithocholic acid (LCA) selectively kills cancer cells while sparing healthy ones. LCA targets cancer cell sensors, triggering mitochondrial self-destruction and bringing the cell down.
Researchers discovered an agent, PEDF, that suppresses brain metastatic activity and shields the brain from tumor-induced damage. This finding represents a significant step forward in managing brain metastases, a major challenge in cancer treatment.
Research suggests that breast cancer survivors who practice MBSR experience improved mood, reduced stress markers, and increased mindfulness. The study highlights the potential benefits of this non-pharmaceutical approach as a complement to traditional treatments.
A Wayne State University researcher is studying the signaling process that triggers breast cancer transformation. The objective of his three-year study is to evaluate the potential roles of two small proteins in breast cancer progression.
Researchers found that patients with initial metastatic breast cancer tend to be older and have lower-grade tumors, while those with early relapse after treatment are younger and have more aggressive cancer. The study emphasizes the importance of increasing awareness about breast care and the need for novel therapeutic strategies to im...
Researchers at Penn developed a new MRI contrast agent that targets acidic environments of tumors, improving diagnosis accuracy. The coating technology allows the particles to be neutral near healthy tissue but become ionized in low pH, attracting them to tumor sites.
Research reveals that cancer cells use a positive feedback loop involving c-MYC and SIRT1 to drive continuous cell division and tumor growth. This mechanism undermines normal cell regulation, leading to uncontrolled proliferation and treatment resistance in certain types of cancer.
A study by McMaster researchers found consistent evidence that hormone replacement therapy is associated with an increased risk of breast cancer globally. The research suggests that decreased HRT use after the WHI trial led to a decline in breast cancer incidence in many countries.
Researchers at Ohio State University found that normal cells in tumors can enhance cancer cell growth after losing a tumor suppressor gene called Pten. The study suggests interrupting signals between normal cells and cancer cells as a new approach to treating breast cancer.
Research reveals that women at risk for breast cancer are also at a higher risk for heart disease due to mutations in the BRCA1 and BRCA2 genes. The study found that these genes regulate heart function and can lead to increased mortality rates after a heart attack.
A novel study led by UCSF found that mammograms detect slower-growing breast cancers in women over 50, increasing the likelihood of good prognosis without treatment. The research provides a basis for integrating molecular profiling to avoid overtreatment and improve care.
Researchers have discovered a microRNA, miR-520, that suppresses NFkappaB and TGF-b signaling pathways in breast cancer cells. This finding suggests that miR-520 may act as a tumor suppressor and could lead to new treatment options for ER-negative breast cancer.
A study found APBIb use increased from 0.4% to 6.6% between 2000 and 2007, with wide regional disparities and racial/ethnic differences in utilization. The authors suggest unwarranted variation in practice may be present, highlighting the need for further research on APBI effectiveness.
Researchers have developed a vaccine that successfully attacks breast cancer in mice, with implications for treating ovarian, colorectal and pancreatic cancer. The vaccine targets MUC1, a protein found on over 90% of human breast and pancreatic cancer cases.
A new test developed by QUT PhD student Helen McCosker can predict the likelihood of breast cancer growth, dormancy, or spread to other organs. The test analyzes tissue surrounding cancer cells and offers personalized treatment plans for patients.
A new analysis found that breast cancer survivors may experience mental abilities problems several years after treatment, regardless of therapy type. Chemotherapy was linked to persistent cognitive issues, while radiation also caused similar problems in some cases.
Scientists developed a vaccine that reduces tumors by 80% in mouse models of breast and pancreatic cancer. The vaccine uses a unique carbohydrate signature to train the immune system to target cancer cells.
Researchers found that between 1992 and 2005, the percentage of patients who had multiple imaging visits nearly quadrupled, from 4.9% to 19.4%. A single imaging visit increasingly includes multiple types of imaging, with the rate rising from 4.3% to 27.1%.
Women with newly diagnosed inflammatory breast cancer who have stray tumor cells in their blood should receive aggressive treatment, regardless of imaging results. Researchers found no correlation between circulating tumor cells and survival rates in these patients.
Researchers found that loss of the retinoblastoma tumor suppressor gene (RB) in triple negative breast cancer patients is linked to improved survival rates. This discovery could lead to personalized treatment approaches for these patients.
A new study by Northwestern University finds that joint pain is the most common reason for women to stop taking aromatase inhibitors, a common breast cancer medication. The research also highlights a gap between clinicians' reported side effects and women's actual experiences.
A new study found that women with BRCA1 or BRCA2 mutations inherited from their fathers tend to be diagnosed with breast cancer a decade earlier than those who inherit the genes from their mothers. The research analyzed 130 patients and discovered significant differences in age of diagnosis based on parent-of-origin effects.
Researchers found that restricting carbs two days a week leads to greater weight loss and improved insulin levels compared to daily calorie restriction. This approach may be a more effective way to prevent breast cancer and other diseases, according to the study.
Researchers found that increased starch intake was associated with a greater risk of breast cancer recurrence in women. Women who increased their starch intake over one year were at a higher risk for recurring, with changes in starch intake accounting for 48% of the change in carbohydrate intake.
Cancer incidence rates have increased while deaths have decreased in Australia over the past quarter century. The study found that Indigenous Australians face higher death rates due to disparities in cancer diagnoses, treatments, and other illnesses.
Women who use breast-enhancing dietary supplements containing zearalenone (ZEN) may be increasing their risk of breast cancer. The review highlights concerns over ZEN's effects on the human reproductive system and breast cancer, as well as its links to premature puberty and infertility.
Researchers have developed ways to exploit the addictions of cancers to kill them without harming normal tissues. The study identified SUMOylation as a key biochemical process involved in coping with cancer cell stress, and inhibiting this enzyme may be a therapeutic strategy for myc-driven cancers.
Only about one-third of women undergo immediate reconstructive breast surgery after mastectomy, which improves psychological well-being and quality of life. Factors such as age, insurance status, and hospital location influence the likelihood of reconstruction, highlighting the need for increased access to this procedure.
Researchers precisely measured protein levels in 1,400 tumor biopsies and found no correlation between HER3 protein levels and Herceptin treatment outcome. The study suggests that single biomarkers like HER3 are not predictive of benefit from Herceptin treatment.
A large study showed that obese patients have poorer long-term outcomes than normal-weight patients when not treated with trastuzumab. Adding trastuzumab to treatment may potentially equalize disease-free survival rates among all patient groups.